PL3322734T3 - Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5 - Google Patents

Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5

Info

Publication number: PL3322734T3
Authority: PL; Poland
Prior art keywords: multivalent; fusion proteins; proteins binding; multispecific fusion; multispecific
Prior art date: 2015-07-16

Application number

PL16825315T

Other languages

English (en)

Inventor

John C. Timmer

Kyle S. JONES

Amir S. RAZAI

Abrahim HUSSAIN

Katelyn M. WILLIS

Quinn Deveraux

Brendan P. Eckelman

Original Assignee

Inhibrx, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-16

Filing date

2016-07-18

Publication date

2021-05-04

2016-07-18 Application filed by Inhibrx, Inc. filed Critical Inhibrx, Inc.

2021-05-04 Publication of PL3322734T3 publication Critical patent/PL3322734T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL16825315T 2015-07-16 2016-07-18 Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5 PL3322734T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562193309P	2015-07-16	2015-07-16
PCT/US2016/042862 WO2017011837A2 (en)	2015-07-16	2016-07-18	Multivalent and multispecific dr5-binding fusion proteins
EP16825315.1A EP3322734B1 (en)	2015-07-16	2016-07-18	Multivalent and multispecific dr5-binding fusion proteins

Publications (1)

Publication Number	Publication Date
PL3322734T3 true PL3322734T3 (pl)	2021-05-04

Family

ID=57757772

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16825315T PL3322734T3 (pl)	2015-07-16	2016-07-18	Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5

Country Status (24)

Country	Link
US (4)	US10308720B2 (pl)
EP (2)	EP3322734B1 (pl)
JP (4)	JP6807606B2 (pl)
KR (2)	KR102760380B1 (pl)
CN (2)	CN107922491B (pl)
AU (3)	AU2016291701B2 (pl)
CY (1)	CY1123615T1 (pl)
DK (1)	DK3322734T3 (pl)
ES (1)	ES2833773T3 (pl)
HR (1)	HRP20201785T1 (pl)
HU (1)	HUE051896T2 (pl)
IL (3)	IL292037A (pl)
LT (1)	LT3322734T (pl)
MX (2)	MX2018000523A (pl)
NZ (1)	NZ777930A (pl)
PL (1)	PL3322734T3 (pl)
PT (1)	PT3322734T (pl)
RS (1)	RS61062B1 (pl)
RU (2)	RU2748620C2 (pl)
SG (1)	SG10201912410TA (pl)
SI (1)	SI3322734T1 (pl)
SM (1)	SMT202100066T1 (pl)
WO (1)	WO2017011837A2 (pl)
ZA (1)	ZA201800238B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN120607624A (zh)	2017-04-11	2025-09-09	因荷布瑞克斯生物科学公司	具有受限cd3结合的多特异性多肽构建体及其使用方法
CA3086653A1 (en) *	2017-12-28	2019-07-04	Julius-Maximilians-Universitat Wurzburg	Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa)
CN110305210B (zh) *	2018-03-27	2023-02-28	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
AU2019251488B2 (en)	2018-04-11	2026-02-12	Inhibrx Biosciences, Inc.	Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses
WO2020047705A1 (zh) *	2018-09-03	2020-03-12	安菲尼生命科技有限公司	Dr5单域抗体及其用途
GB201903767D0 (en) *	2019-03-19	2019-05-01	Quadrucept Bio Ltd	Multimers, tetramers & octamers
AU2020360962A1 (en) *	2019-10-01	2022-04-14	Epsilogen Ltd	Hybrid antibody
US20230322953A1 (en) *	2020-06-30	2023-10-12	Harbour Biomed (Shanghai) Co., Ltd	Binding protein having h2l2 and hcab structures
US20230303698A1 (en) *	2020-06-30	2023-09-28	Harbour Biomed (Shanghai) Co., Ltd	Multispecific binding protein of immune cell engager, preparation therefor and application thereof
TWI818276B (zh) *	2020-06-30	2023-10-11	大陸商和鉑醫藥（上海）有限責任公司	Fab-HCAb結構的結合蛋白
MX2023009567A (es) *	2021-02-19	2023-08-22	Inhibrx Inc	Formulaciones de polipeptidos de union a dr5.
CA3247628A1 (en) *	2022-04-08	2023-10-12	Inhibrx Biosciences, Inc.	POLYTHERAPY INCLUDING A DR5 AGONIST AND A PLK1 OR CDK INHIBITOR
AU2023275703A1 (en) *	2022-05-23	2024-11-21	Inhibrx Biosciences, Inc.	Dr5 agonist and iap antagonist combination therapy
CN117285644A (zh) *	2022-06-16	2023-12-26	清华大学	一种相变调节元件及其用途
US20260036590A1 (en)	2022-09-28	2026-02-05	Valink Therapeutics Ltd	Multivalent proteins and screening methods
AR133108A1 (es) *	2023-06-29	2025-08-27	Odyssey Therapeutics Inc	Proteínas de unión a antígeno anti-trailr2 y sus usos

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ241119A (en) *	1990-12-20	1993-06-25	Ixsys Inc	Manipulating nucleic acid to optimize the binding characteristics of the encoded binding protein
US20020147140A1 (en) *	2000-01-31	2002-10-10	Rosen Craig A.	Nucleic acids, proteins, and antibodies
KR20070010046A (ko) *	2004-04-06	2007-01-19	제넨테크, 인크.	Ｄｒ5 항체 및 그의 용도
JP2008526205A (ja)	2004-12-31	2008-07-24	ジェネンテック・インコーポレーテッド	Ｂｒ３に結合するポリペプチド及びその使用
WO2006091734A2 (en)	2005-02-24	2006-08-31	Cemines, Inc.	Compositions and methods for classifying biological samples
CA2619725C (en)	2005-08-18	2016-06-07	Ramot At Tel Aviv University Ltd.	Single chain antibodies against beta-amyloid peptide
EA013878B1 (ru)	2005-12-06	2010-08-30	Домантис Лимитед	Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
WO2007097923A2 (en)	2006-02-20	2007-08-30	Phylogica Limited	Method of constructing and screening libraries of peptide structures
JP2008133206A (ja)	2006-11-28	2008-06-12	Yokohama City Univ	緑膿菌に対して感染防御能を誘導できる医薬組成物
MX2010005871A (es)	2007-11-30	2010-06-09	Kalobios Pharmaceuticals Inc	Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
SI2285408T1 (sl)	2008-06-05	2019-02-28	Ablynx N.V.	Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
US20110166076A1 (en) *	2008-09-10	2011-07-07	Bac Ip B.V.	Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2010107778A1 (en)	2009-03-18	2010-09-23	Wake Forest University Health Sciences	Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
US20100281003A1 (en)	2009-04-02	2010-11-04	New York University	System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) *	2009-11-13	2012-01-04	厦门大学	抗人死亡受体5的单链抗体基因
WO2011073180A1 (en)	2009-12-14	2011-06-23	Ablynx N.V.	Single variable domain antibodies against ox40l, constructs and therapeutic use
US9120855B2 (en) *	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
WO2011134060A1 (en)	2010-04-27	2011-11-03	National Research Council Of Canada	Anti-icam-1 single domain antibody and uses thereof
KR101912957B1 (ko)	2010-09-27	2018-10-29	모르포시스 아게	다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉
WO2012055030A1 (en)	2010-10-25	2012-05-03	National Research Council Of Canada	Clostridium difficile-specific antibodies and uses thereof
KR20130133212A (ko)	2010-12-23	2013-12-06	인터셀 오스트리아 아게	입원 및 다른 환자에서 OprF/I 물질 및 이의 용도
UY34254A (es)	2011-08-17	2013-04-05	Glaxo Group Ltd	Proteínas y péptidos modificados.
SMT202000091T1 (it)	2011-10-13	2020-05-08	Bristol Myers Squibb Co	Polipeptidi anticorpali che antagonizzano cd40l
JP2014533249A (ja)	2011-11-07	2014-12-11	メディミューン，エルエルシー	多重特異性を持つ多価結合タンパク質およびその使用
CA2859226C (en)	2011-12-20	2020-07-21	Adaerata, Limited Partnership	Single domain antibodies as inhibitors of pcsk9
WO2013128031A1 (en)	2012-03-02	2013-09-06	Ablynx Nv	Pseudomonas aeruginosa pcrv binding single variable domain antibodies
EP2847229B1 (en)	2012-05-07	2022-09-07	Elasmogen Limited	Single domain binding molecule
EP2684896A1 (en) *	2012-07-09	2014-01-15	International-Drug-Development-Biotech	Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
CN104781277A (zh)	2012-09-13	2015-07-15	诺华股份有限公司	具有末端修饰的抗原结合分子
AU2013341349A1 (en)	2012-11-06	2015-05-21	Medimmune Limited	Combination therapies using anti-Pseudomonas Psl and PcrV binding molecules
CN102924600B (zh) *	2012-11-14	2013-10-30	河南大学	死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
EP3004170A1 (en)	2013-05-28	2016-04-13	VIB vzw	Single domain antibodies against sod1 and their use in medicine
EP3093338B1 (en) *	2014-01-10	2021-02-17	Teikyo Heisei University	Recombinant anaerobic gram-positive bacteria

2016
- 2016-07-18 HU HUE16825315A patent/HUE051896T2/hu unknown
- 2016-07-18 NZ NZ777930A patent/NZ777930A/en unknown
- 2016-07-18 MX MX2018000523A patent/MX2018000523A/es unknown
- 2016-07-18 CN CN201680041274.2A patent/CN107922491B/zh active Active
- 2016-07-18 IL IL292037A patent/IL292037A/en unknown
- 2016-07-18 RU RU2018102803A patent/RU2748620C2/ru active
- 2016-07-18 US US15/213,296 patent/US10308720B2/en active Active
- 2016-07-18 RU RU2021111382A patent/RU2021111382A/ru unknown
- 2016-07-18 KR KR1020187000975A patent/KR102760380B1/ko active Active
- 2016-07-18 WO PCT/US2016/042862 patent/WO2017011837A2/en not_active Ceased
- 2016-07-18 SM SM20210066T patent/SMT202100066T1/it unknown
- 2016-07-18 PT PT168253151T patent/PT3322734T/pt unknown
- 2016-07-18 SI SI201631005T patent/SI3322734T1/sl unknown
- 2016-07-18 SG SG10201912410TA patent/SG10201912410TA/en unknown
- 2016-07-18 EP EP16825315.1A patent/EP3322734B1/en active Active
- 2016-07-18 PL PL16825315T patent/PL3322734T3/pl unknown
- 2016-07-18 CN CN202111039963.9A patent/CN114106178A/zh active Pending
- 2016-07-18 LT LTEP16825315.1T patent/LT3322734T/lt unknown
- 2016-07-18 HR HRP20201785TT patent/HRP20201785T1/hr unknown
- 2016-07-18 DK DK16825315.1T patent/DK3322734T3/da active
- 2016-07-18 ES ES16825315T patent/ES2833773T3/es active Active
- 2016-07-18 RS RS20201315A patent/RS61062B1/sr unknown
- 2016-07-18 AU AU2016291701A patent/AU2016291701B2/en active Active
- 2016-07-18 KR KR1020257002277A patent/KR20250017305A/ko active Pending
- 2016-07-18 JP JP2018501345A patent/JP6807606B2/ja active Active
- 2016-07-18 IL IL307994A patent/IL307994A/en unknown
- 2016-07-18 EP EP20189995.2A patent/EP3798232A1/en active Pending
2018
- 2018-01-07 IL IL256772A patent/IL256772B/en unknown
- 2018-01-12 ZA ZA2018/00238A patent/ZA201800238B/en unknown
- 2018-01-12 MX MX2023002379A patent/MX2023002379A/es unknown
2019
- 2019-04-18 US US16/387,754 patent/US11117973B2/en active Active
2020
- 2020-11-16 CY CY20201101085T patent/CY1123615T1/el unknown
- 2020-11-26 JP JP2020196358A patent/JP7244938B2/ja active Active
2021
- 2021-08-05 US US17/394,900 patent/US11976126B2/en active Active
2022
- 2022-11-30 JP JP2022191038A patent/JP2023022214A/ja active Pending
- 2022-12-21 AU AU2022291498A patent/AU2022291498A1/en not_active Abandoned
2024
- 2024-04-04 US US18/626,699 patent/US20240376220A1/en active Pending
2025
- 2025-03-03 JP JP2025032594A patent/JP2025084923A/ja active Pending
2026
- 2026-01-16 AU AU2026200317A patent/AU2026200317A1/en active Pending

Also Published As

Publication number	Publication date
RU2748620C2 (ru)	2021-05-28
CN107922491A (zh)	2018-04-17
RU2018102803A3 (pl)	2019-12-27
ZA201800238B (en)	2021-07-28
DK3322734T3 (da)	2020-10-26
BR112018000584A2 (pt)	2018-09-11
EP3322734A4 (en)	2019-04-17
HRP20201785T1 (hr)	2021-01-22
PT3322734T (pt)	2020-11-30
IL256772A (en)	2018-03-29
US11976126B2 (en)	2024-05-07
WO2017011837A3 (en)	2017-03-02
MX2023002379A (es)	2023-03-21
RU2021111382A (ru)	2021-05-21
US20170015753A1 (en)	2017-01-19
US11117973B2 (en)	2021-09-14
HUE051896T2 (hu)	2021-03-29
US20190309083A1 (en)	2019-10-10
JP6807606B2 (ja)	2021-01-06
SG10201912410TA (en)	2020-02-27
KR102760380B1 (ko)	2025-01-31
CN107922491B (zh)	2021-09-28
ES2833773T3 (es)	2021-06-15
EP3798232A1 (en)	2021-03-31
AU2016291701A1 (en)	2018-01-25
JP2021046414A (ja)	2021-03-25
CN114106178A (zh)	2022-03-01
KR20180030518A (ko)	2018-03-23
IL256772B (en)	2022-05-01
IL307994A (en)	2023-12-01
MX2018000523A (es)	2018-04-13
AU2016291701B2 (en)	2022-09-29
HK1254433A1 (en)	2019-07-19
EP3322734B1 (en)	2020-09-09
US10308720B2 (en)	2019-06-04
EP3322734A2 (en)	2018-05-23
JP2025084923A (ja)	2025-06-03
CY1123615T1 (el)	2022-03-24
RS61062B1 (sr)	2020-12-31
IL292037A (en)	2022-06-01
AU2026200317A1 (en)	2026-02-05
AU2022291498A1 (en)	2023-02-02
NZ777930A (en)	2025-05-02
JP2023022214A (ja)	2023-02-14
WO2017011837A2 (en)	2017-01-19
KR20250017305A (ko)	2025-02-04
RU2018102803A (ru)	2019-08-19
SMT202100066T1 (it)	2021-03-15
CA2991634A1 (en)	2017-01-19
NZ738850A (en)	2024-11-29
US20220064318A1 (en)	2022-03-03
JP7244938B2 (ja)	2023-03-23
SI3322734T1 (sl)	2021-02-26
JP2018522888A (ja)	2018-08-16
US20240376220A1 (en)	2024-11-14
LT3322734T (lt)	2021-02-10

Publication	Publication Date	Title
PL3322734T3 (pl)	2021-05-04	Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5
SG10201913807QA (en)	2020-03-30	Multivalent and multispecific gitr-binding fusion proteins
SG10201912405TA (en)	2020-02-27	Multivalent and multispecific 41bb-binding fusion proteins
IL262437A (en)	2018-12-31	Bispecific binding proteins and uses thereof
IL246921B (en)	2019-09-26	Binding proteins and methods of use thereof
IL256416B (en)	2021-12-01	Multispecific antigen-binding molecules and uses thereof
DK3292141T3 (da)	2020-04-20	Fusionsproteiner
IL254516B (en)	2021-10-31	Proteins specific for cd137
HUE050750T2 (hu)	2021-01-28	CTLA-4 elleni antitestek és eljárások alkalmazásukra
DK3180363T3 (da)	2019-11-04	Sirp-alpha-immunoglobulin fusionsproteiner
DK3242892T3 (da)	2022-01-24	Modificerede april-bindende antistoffer
DK3316909T3 (da)	2023-11-13	Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK2970464T3 (da)	2020-08-03	Anti-lag-3-bindende proteiner
IL253341B (en)	2022-04-01	Methods and compositions for combination immunotherapy
DK3107562T3 (da)	2019-12-16	P97-ids-fusionsproteiner
DK3182985T3 (da)	2020-04-06	Fibroinafledt proteinsammensætning
DK3368655T3 (da)	2020-09-14	Forbedret proteinekspression og fremgangsmåder dertil
DK3498292T3 (da)	2022-01-03	Uspa2-proteinkonstruktioner og anvendelser deraf
IL250796A0 (en)	2017-04-30	Binding proteins specific for lox1 and uses thereof
EP3738976C0 (en)	2025-07-23	IL-17A-BINDING FUSION PROTEIN
DK3128997T3 (da)	2020-08-24	Bindingmolekyler specifikke for il-21 og anvendelser deraf
DK3164410T3 (da)	2022-03-07	Protein-indvinding
DK3110837T3 (da)	2019-09-16	Tatk-cdkl5-fusionsproteiner, sammensætninger, formule-ringer og anvendelse deraf
DK3380496T3 (da)	2020-08-24	Forbedret proteinproduktion og fremgangsmåder hertil
CL2016002136A1 (es)	2017-08-11	Proteinas de fusión uti